Quote | Race Oncology (OTCMKTS:RAONF)
Last: | $0.83 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $0.83 |
High: | $0 |
Low: | $0 |
Volume: | 261 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Race Oncology (OTCMKTS:RAONF)
(NewsDirect) Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett joins Proactive’s Jonathan Jackson to discuss promising preclinical findings. Research indicated that combining bisantrene with decitabine greatly enhances the destruction of cancer cells across a wide variety of...
(NewsDirect) Race Oncology Ltd (ASX:RAC) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of bi...
Message Board Posts | Race Oncology (OTCMKTS:RAONF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Race Oncology Company Name:
RAONF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Dr Daniel Tillett joins Proactive’s Jonathan Jackson to discuss promising preclinical findings. Research indicated that combining bisantrene with decitabine greatly enhances the destruction of cancer cells across a wide variety of...
(NewsDirect) Race Oncology Ltd (ASX:RAC) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of bi...
(NewsDirect) Race Oncology Ltd (ASX:RAC) executive director Pete Smith speaks with Proactive alongside the company’s recently appointed CEO - 25-year veteran of the biotech space, Dr Daniel Tillett. In this pivotal role, Dr Tillett will work closely with Dr Smith to steer the company's...